SCHEMBL310791

SCHEMBL310791

CC(C(=O)O)C1CN(C2=Nc3cc(Cl)ccc3Oc3ccccc32)CCN1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 10/20 0.61
DRD4 P21917 5/20 0.61
DRD2 P14416 4/20 0.61
MEN1 O00255 2/20 0.55
LMNA P02545 2/20 0.55
CYP1A2 P05177 2/20 0.55
CYP3A4 P08684 2/20 0.55
CYP2D6 P10635 2/20 0.55
PMP22 Q01453 2/20 0.55
KMT2A Q03164 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
ABCB11 O95342 1/20 0.55
CYP2C9 P11712 1/20 0.55
BLM P54132 1/20 0.55
HTR2C P28335 5/20 0.53
ADRA2A P08913 4/20 0.53
HTR2A P28223 4/20 0.53
HRH2 P25021 3/20 0.53
HRH1 P35367 3/20 0.53
DRD1 P21728 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310790 1.00 HRH4 (0.61) HRH4DRD4DRD2MEN1LMNA
SCHEMBL301395 0.89 HRH4 (0.59) HRH4DRD4DRD2MEN1LMNA
SCHEMBL300929 0.88 HRH4 (0.57) HRH4DRD4DRD2MEN1LMNA
SCHEMBL311113 0.87 HRH4 (0.56) HRH4DRD4DRD2MEN1LMNA
SCHEMBL311114 0.87 HRH4 (0.56) HRH4DRD4DRD2MEN1LMNA
SCHEMBL300234 0.86 HRH4 (0.55) HRH4DRD4DRD2MEN1LMNA
SCHEMBL300235 0.86 HRH4 (0.55) HRH4DRD4DRD2MEN1LMNA
SCHEMBL311618 0.86 HRH4 (0.55) HRH4DRD4DRD2MEN1LMNA
SCHEMBL300267 0.86 HRH4 (0.55) HRH4DRD4DRD2MEN1LMNA
SCHEMBL300295 0.86 HRH4 (0.57) HRH4DRD4DRD2MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093237-B2 11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazapine compounds; psychological disorders, sleep disorders; antipsychotic agents that modulate monoaminergic neurotransmitter receptor subtypes; side effect reduction ARYX THERAPEUTICS, INC. (US) 2012-01-10 US claimed